Status:
UNKNOWN
Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
Lead Sponsor:
University of Manchester
Collaborating Sponsors:
Cancer Research UK
Conditions:
Lung Cancer Stage III
Eligibility:
All Genders
18+ years
Brief Summary
In stage 3 NSCLC, treatment and follow-up are generally performed in a 'one-size-fits-all' manner. In the setting of metastatic lung cancer there has been considerable success identifying biomarkers, ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histological or cytologically confirmed NSCLC.
- Unsuitable for surgery due to tumour or patient factors.
- Stage 3 A, B or C (TNM version 8).
- Planned to receive radical radiotherapy OR sequential chemoradiotherapy OR concurrent chemoradiotherapy +/- consolidation immunotherapy.
- Predicted life expectancy \>12 weeks.
- Ability to provide written informed consent.
- Willingness to comply with study procedures.
- Exclusion criteria:
- Mixed non-small cell and small cell tumours.
- Adjuvant radiotherapy post-surgery.
- Participation in a study of an interventional study as part of lung cancer treatment.
- Recent/active malignant disease which might impact study results.
- Psychotic disorders/cognitive impairment.
Exclusion
Key Trial Info
Start Date :
March 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 24 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06086574
Start Date
March 24 2023
End Date
September 24 2025
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Christie NHS Foundation Trust
Manchester, United Kingdom